ATE169503T1 - Rekombinante viren und ihre verwendung bei der gentherapie - Google Patents

Rekombinante viren und ihre verwendung bei der gentherapie

Info

Publication number
ATE169503T1
ATE169503T1 AT94913650T AT94913650T ATE169503T1 AT E169503 T1 ATE169503 T1 AT E169503T1 AT 94913650 T AT94913650 T AT 94913650T AT 94913650 T AT94913650 T AT 94913650T AT E169503 T1 ATE169503 T1 AT E169503T1
Authority
AT
Austria
Prior art keywords
pct
gene therapy
recombinant viruses
sec
date
Prior art date
Application number
AT94913650T
Other languages
English (en)
Inventor
Patrick Benoit
Patrice Denefle
Michel Perricaudet
Sandrine Seguret
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of ATE169503T1 publication Critical patent/ATE169503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94913650T 1993-04-30 1994-04-15 Rekombinante viren und ihre verwendung bei der gentherapie ATE169503T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9305125A FR2704556B1 (fr) 1993-04-30 1993-04-30 Virus recombinants et leur utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
ATE169503T1 true ATE169503T1 (de) 1998-08-15

Family

ID=9446605

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913650T ATE169503T1 (de) 1993-04-30 1994-04-15 Rekombinante viren und ihre verwendung bei der gentherapie

Country Status (17)

Country Link
US (2) US5866551A (de)
EP (1) EP0701450B1 (de)
JP (1) JPH08509373A (de)
KR (1) KR100330142B1 (de)
AT (1) ATE169503T1 (de)
AU (1) AU696199B2 (de)
BR (1) BR9406689A (de)
CA (1) CA2161679A1 (de)
DE (1) DE69412486T2 (de)
DK (1) DK0701450T3 (de)
ES (1) ES2120036T3 (de)
FI (1) FI955154A0 (de)
FR (1) FR2704556B1 (de)
GR (1) GR3027660T3 (de)
NO (1) NO954286D0 (de)
WO (1) WO1994025073A1 (de)
ZA (1) ZA942980B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
FR2731229B1 (fr) * 1995-03-02 1997-04-30 Rhone Poulenc Rorer Sa Therapie genique de l'atherosclerose par production de hdl par les lignees monocytaires
US5734699A (en) * 1995-05-04 1998-03-31 Interwave Communications International, Ltd. Cellular private branch exchanges
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
CZ326896A3 (cs) * 1996-11-07 1998-05-13 Milo Olomouc, A. S. Tuk se specifickými protisklerotickými účinky
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
KR100516561B1 (ko) 1996-12-06 2005-09-22 아벤티스 파마슈티칼스 인크. 사람 리파제-유사 유전자에 의해 암호화된 폴리펩타이드, 조성물 및 방법
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
JP4344136B2 (ja) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) * 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
AU2005207053A1 (en) * 2004-01-23 2005-08-04 Virxsys Corporation Expression of ApoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
CA2602946A1 (en) * 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
CA2665403C (en) * 2006-10-04 2015-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61135587A (ja) * 1984-12-03 1986-06-23 Norin Suisansyo Shokuhin Sogo Kenkyusho アポリポタン白質ｅ遺伝子およびその調製法
ATE89314T1 (de) * 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
JPS63237795A (ja) * 1987-03-24 1988-10-04 Otsuka Pharmaceut Factory Inc アポリポタンパク質の製造法
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
FR2666813A1 (fr) * 1990-09-18 1992-03-20 Rhone Poulenc Sante Procede microbiologique de preparation de l'apolipoproteine aiv humaine ou de derives de celle-ci.
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1993003769A1 (en) * 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6777977B1 (en) * 2002-05-01 2004-08-17 Actel Corporation Three input field programmable gate array logic circuit configurable as a three input look up table, a D-latch or a D flip-flop
CA2419216C (en) * 2003-02-19 2005-03-01 Jan Nyquist Method and apparatus for joining plastic pipe

Also Published As

Publication number Publication date
FR2704556B1 (fr) 1995-07-13
USRE38556E1 (en) 2004-07-13
ZA942980B (en) 1995-01-18
CA2161679A1 (fr) 1994-11-10
NO954286L (no) 1995-10-26
NO954286D0 (no) 1995-10-26
BR9406689A (pt) 1996-01-30
FI955154L (fi) 1995-10-27
WO1994025073A1 (fr) 1994-11-10
FR2704556A1 (fr) 1994-11-04
ES2120036T3 (es) 1998-10-16
AU696199B2 (en) 1998-09-03
EP0701450B1 (de) 1998-08-12
FI955154A7 (fi) 1995-10-27
US5866551A (en) 1999-02-02
EP0701450A1 (de) 1996-03-20
DE69412486T2 (de) 1999-03-11
GR3027660T3 (en) 1998-11-30
KR100330142B1 (ko) 2002-09-27
AU6572294A (en) 1994-11-21
DK0701450T3 (da) 1999-02-08
FI955154A0 (fi) 1995-10-27
JPH08509373A (ja) 1996-10-08
DE69412486D1 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
DE69412486D1 (de) Rekombinante viren und ihre verwendung bei der gentherapie
DE69429260D1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
NO952229D0 (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
DE69428791D1 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
EP0975351A4 (de) Behandlung der multiplen sklerose durch einnahme oder inhalation von copolymer-1
EP0705100A4 (de) Therapeutische substituierte guanidine
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
ATE179211T1 (de) Menschliche il-3-varianten
GR3026600T3 (en) Human il-4 mutant proteins.
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
EE03123B1 (et) Kinoliini derivaadid, nende valmistamise protsess, neid sisaldavad ravimpreparaadid ja nende kasutamine
ATE145135T1 (de) Verwendung von riluzol zum schutz gegen strahlenschäden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee